Table 1. . Key agents and regimens that are approved/recommended for newly diagnosed multiple myeloma and relapsed/refractory multiple myeloma.

Class	Agent	Initial approval	NDMM regimens	RRMM regimens
Proteasome inhibitors	Bortezomib	2003 US FDA, 2004 EMA	Vd, VCd, VTd, VRd, VMP, PAD	V ± d, VCd, PAD, VTd, VRd, Benda-Vd, V-Pom-d
	Carfilzomib	2012 FDA, 2015 EMA	KRd, KCd	Kd, KRd, KCd, K-Pom-d
	Ixazomib	2015 FDA, 2016 EMA	IRd	IRd, Id, I-Pom-d
Immunomodulatory drugs	Thalidomide	2006 FDA, 2008 EMA	Td, MPT, CTd, VTd, VTd-PACE	VTd-PACE
	Lenalidomide	2006 FDA, 2007 EMA	Rd, MPR-R, CRd	Rd, Benda-Rd, CRd
	Pomalidomide	2013 FDA and EMA	–	Pom-d, Pom-Cd
Monoclonal antibodies	Daratumumab	2015 FDA, 2016 EMA	Dara-VMP	Dara-Rd, Dara-Vd, Dara, Dara-Pom-d
	Elotuzumab	2015 FDA, 2016 EMA	–	Elo-Rd, Elo-Vd, Elo-Pom-d
Histone deacetylase inhibitors	Panobinostat	2015 FDA and EMA	–	Pano-Vd, Pano-K, Pano-Rd

Table based on references [10–12,41].

Benda-Rd: Bendamustine, lenalidomide, dexamethasone; Benda-Vd: Bendamustine, bortezomib, dexamethasone; CRd: Cyclophosphamide, lenalidomide, dexamethasone; CTd: Cyclophosphamide, thalidomide, dexamethasone; d: Dexamethasone; Dara: daratumumab; Dara-pom-d: Daratumumab, pomalidomide, dexamethasone; Dara-Rd: Daratumumab, lenalidomide, dexamethasone; Dara-Vd: Daratumumab, bortezomib, dexamethasone; Dara-VMP: Daratumumab, bortezomib, melphalan, prednisone; Elo-Pom-d: Elotuzumab, pomalidomide, dexamethasone; Elo-Rd: Elotuzumab, lenalidomide, dexamethasone; Elo-Vd: Elotuzumab, bortezomib, dexamethasone; EMA: European Medicines Agency; Id: Ixazomib, dexamethasone; I-Pom-d: Ixazomib, pomalidomide, dexamethasone; IRd: Ixazomib, lenalidomide, dexamethasone; KCd: Carfilzomib, cyclophosphamide, dexamethasone; Kd: Carfilzomib, lenalidomide; K-Pom-d: Carfilzomib, pomalidomide, dexamethasone; KRd: Carfilzomib, lenalidomide, dexamethasone; MPR-R: Melphalan, prednisone, lenalidomide, plus lenalidomide maintenance; MPT: Melphalan, prednisone, thalidomide; NDMM: Newly diagnosed multiple myeloma; PAD: Bortezomib, doxorubicin, dexamethasone; Pano-K: Panobinostat, carfilzomib; Pano-Rd: Panobinostat, lenalidomide, dexamethasone; Pano-Vd: Panobinostat, bortezomib, dexamethasone; Pom-Cd: Pomalidomide, cyclophosphamide, dexamethasone; Pom-d: Pomalidomide, dexamethasone; Rd: Lenalidomide, dexamethasone; RRMM: Relapsed/refractory multiple myeloma; Td: Thalidomide, dexamethasone; V: Bortezomib; VCd: Bortezomib, cyclophosphamide, dexamethasone; Vd: Bortezomib, dexamethasone; VMP: Bortezomib, melphalan, prednisone; V-Pom-d: Bortezomib, pomalidomide, dexamethasone; VRd: Bortezomib, lenalidomide, dexamethasone; VTd: Bortezomib, thalidomide, dexamethasone; VTd-PACE: Bortezomib, thalidomide, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, etoposide.